First round of Abstract Submissions is open now..!
Don't miss the opportunity! Submit your abstract for the first round by December 15, 2025.
First round of Abstract Submissions is open now..!
Don't miss the opportunity! Submit your abstract for the first round by December 15, 2025.
The crucial stage of drug development, where promising screening hits are developed into premium lead compounds with optimal potency, selectivity, and drug-like qualities, is examined in this session. Participants will examine tried-and-true tactics, state-of-the-art resources, and actual case studies that show how successful hit-to-lead optimization lowers downstream attrition and speeds up preclinical success.